Ligand Pharmaceuticals (LGND) Operating Expenses (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Operating Expenses data on file, last reported at $34.4 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 57.87% year-over-year to $34.4 million; the trailing twelve-month figure through Mar 2026 stood at $179.9 million (down 26.06% YoY), and the FY2025 full-year result was $227.1 million, up 19.68% from the prior year.
• Operating Expenses eased to $34.4 million in Q1 2026, from $45.8 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $81.5 million in Q1 2025 to a low of $28.0 million in Q1 2024.
• A 5-year average of $45.1 million and a median of $41.5 million in 2022 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses jumped 191.35% in 2025 and sank 57.87% in 2026, its largest moves.
• Tracing LGND's Operating Expenses over 5 years: stood at $70.5 million in 2022, then slumped by 55.37% to $31.5 million in 2023, then soared by 66.72% to $52.4 million in 2024, then slipped by 12.63% to $45.8 million in 2025, then slipped by 25.03% to $34.4 million in 2026.
• Business Quant data shows LGND's Operating Expenses at $34.4 million in Q1 2026, $45.8 million in Q4 2025, and $60.5 million in Q3 2025.